176 related articles for article (PubMed ID: 37493210)
1. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
Singh N; Hocking AM; Buckner JH
Immunol Rev; 2023 Sep; 318(1):81-88. PubMed ID: 37493210
[TBL] [Abstract][Full Text] [Related]
2. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
Berner F; Flatz L
Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
[TBL] [Abstract][Full Text] [Related]
3. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
4. T-cell tolerant fraction as a predictor of immune-related adverse events.
Ostmeyer J; Park JY; von Itzstein MS; Hsiehchen D; Fattah F; Gwin M; Catalan R; Khan S; Raj P; Wakeland EK; Xie Y; Gerber DE
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37580069
[TBL] [Abstract][Full Text] [Related]
5. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
[TBL] [Abstract][Full Text] [Related]
6. Role of B cells in immune-related adverse events following checkpoint blockade.
Dhodapkar KM; Duffy A; Dhodapkar MV
Immunol Rev; 2023 Sep; 318(1):89-95. PubMed ID: 37421187
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
8. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
9. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.
McGonagle D; Bragazzi NL; Amital H; Watad A
Autoimmun Rev; 2020 Feb; 19(2):102456. PubMed ID: 31838166
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
Thanarajasingam U; Abdel-Wahab N
Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.
Lechner MG; Cheng MI; Patel AY; Hoang AT; Yakobian N; Astourian M; Pioso MS; Rodriguez ED; McCarthy EC; Hugo W; Angell TE; Drakaki A; Ribas A; Su MA
J Immunol; 2022 Aug; 209(4):696-709. PubMed ID: 35817515
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Khan S; Gerber DE
Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185
[TBL] [Abstract][Full Text] [Related]
15. Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α.
Dasgupta A; Tsay E; Federman N; Lechner MG; Su MA
Pediatrics; 2022 Apr; 149(4):. PubMed ID: 35274131
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA; Stanzer S; Spiegelberg J; Bauernhofer T; Absenger G; Posch F; Lipp R; Halm M; Szkandera J; Balic M; Gerger A; Smolle MA; Hutterer GC; Klec C; Jost PJ; Kargl J; Stradner M; Pichler M
Cancer Med; 2022 Aug; 11(16):3074-3083. PubMed ID: 35297215
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
18. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
McCombe JA; Sechi E; Zekeridou A
Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
[TBL] [Abstract][Full Text] [Related]
19. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
Williams SG; Mollaeian A; Katz JD; Gupta S
Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]